Science Featured on MSN1mon
This Common Cancer Treatment Might Help Patients Stay Healthier for Longer
Understanding how to keep leukemia in remission for longer in older patients remains a significant challenge in cancer ...
News Medical5y
Azacitidine-Teva
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Azacitidine-Teva contains the active ingredient azacitidine.
Aptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last year
During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax and azacitidine for ...
Zacks.com on MSN4mon
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
The phase III SELECT-MDS-1 study evaluated tamibarotene in combination with azacitidine, a chemotherapy, in newly diagnosed ...
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
EST/21:30 CET– ImCheck Therapeutics announced today it will present updated results from its ongoing open-label, randomized ...
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...